Search Results
Your search for ASCO matches 21291 pages
Showing 11351 - 11400Stage IV Lung Cancer Did Not Stop Me From Climbing Mera Peak
A veteran mountain climber and skier, I’ve been healthy for most of my 61 years, so it was especially shocking to experience a bout of shortness of breath during a moderately intense mountain bike ride with my wife, Jan, in the spring of 2014. A never-smoker, I was used to climbing up high mountain ...
High–Nicotine-Dependent Smokers Less Likely to Quit After Lung Cancer Screening
A new study by Rojewski et al in CHEST investigated the relationships between the degree of nicotine dependence and both the likelihood of successfully quitting smoking and clinical outcomes in a cohort of screened patients. The study found that patients with a higher nicotine dependence...
FDA Identifies Efficacy Issue in Clinical Trials of Pembrolizumab or Atezolizumab as Monotherapy in Urothelial Cancer With Low Expression of PD-L1
On May 18, the U.S. Food and Drug Administration (FDA) alerted health-care professionals, oncology clinical investigators, and the public about decreased survival associated with the use of pembrolizumab (Keytruda) or atezolizumab (Tecentriq) as monotherapy in clinical trials to treat patients with ...
Cancer Support Community Welcomes Kevin Stein, PhD, FAPOS, as Executive Director of Research and Training Institute
The Cancer Support Community recently announced the addition of Kevin Stein, PhD, FAPOS, as Executive Director of its Research and Training Institute. Dr. Stein is Associate Professor in the Behavioral Sciences and Health Education Department of the Rollins School of Public Health at Emory...
Antoni Ribas, MD, Recognized for Research in Cancer Immunology
Antoni Ribas, MD, Professor of Medicine and Director of the Tumor Immunology Program at the University of California Jonsson Comprehensive Cancer Center, has been awarded the sixth American Association of Cancer Research–Cancer Research Institute Lloyd J. Old Award in Cancer Immunology. The award...
Visible Ink Celebrates 10 Years of Live Patient Performances
On April 16, 2018, Memorial Sloan Kettering Cancer Center (MSK) in New York hosted the annual Visible Ink live performances at The Kaye Playhouse at Hunter College. The evening marked the 10th anniversary of the ongoing one-on-one writing program for patients undergoing cancer treatment at MSK....
Treatment of Malignant Pleural Mesothelioma: ASCO Clinical Practice Guideline
As reported by Hedy L. Kindler, MD, of the University of Chicago, and colleagues in the Journal of Clinical Oncology, ASCO has released a clinical practice guideline on the treatment of malignant pleural mesothelioma.1 The guideline was based on a systematic literature search and expert panel...
Stand Up To Cancer Launches Research Team to Detect Precursor Conditions of Multiple Myeloma
Stand Up To Cancer (SU2C) announced a $10 million award to a Stand Up To Cancer Dream Team focused on revolutionizing the treatment of multiple myeloma through the early detection of precursor conditions. In the hope of developing therapies to prevent myeloma in high-risk populations, the project...
Logistics of CAR T-Cell Therapy in Real-World Practice
With the U.S. Food and Drug Administration (FDA) approvals of tisagenlecleucel (Kymriah)1 and axicabtagene ciloleucel (Yescarta),2 chimeric antigen receptor (CAR) T-cell therapy has moved into real-world practice, offering new potentially curative options for incurable hematologic malignancies. Its ...
Focus on the Tennessee Oncology Practice Society
The Tennessee Oncology Practice Society (TOPS) is among the oldest and one of many politically active ASCO State Affiliates. Founded in 1990, the organization has since been a voice for Tennessee’s diverse community of oncology professionals, advocating for patient access to the best available care ...
Treating Insomnia in Cancer Survivors
A Patient-Centered Outcomes Research Institute–supported randomized clinical trial of cancer survivors showed that 8 weeks of either acupuncture or cognitive behavioral therapy for insomnia (CBT-I) decreased the severity of insomnia among cancer survivors, though improvements were greatest among...
Supporting Patients During and After Cancer Treatment: Evidence-Informed Approach to Lifestyle and Behavior Change
The ASCO Post’s Integrative Oncology series is intended to facilitate the availability of evidence-based information on integrative and complementary therapies sometimes used by patients with cancer. In this installment, Lorenzo Cohen, PhD, and Alison Jefferies, BA, MEd, summarize research...
Florida Cancer Centers Awarded $1.36 Million to Minimize Disparities in Pancreatic Cancer
The Florida Department of Health’s James and Esther King Biomedical Research Program has granted Moffitt Cancer Center, the University of Florida Health Cancer Center, the Sylvester Comprehensive Cancer Center at the University of Miami, and numerous collaborating centers with $1.36 million to...
ACCP Statement on Organ-Impaired Patients in Oncology Trials
The American College of Clinical Pharmacology (ACCP) recently published a Policy Statement reviewing ways in which clinical pharmacology can and should make an effort to include organ-impaired patients in oncology trials. The announcement identifies key discussions needed among industry,...
New International Translations of NCCN Guidelines for Patients
The National Comprehensive Cancer Network® (NCCN®) has published a newly translated Italian version of the NCCN Guidelines for Patients® for stomach cancer, funded by No Stomach for Cancer. Over the past year, the NCCN Foundation also worked with the Kidney Cancer Association to translate patient...
Closing the Gap in Oncology Care for Adolescents and Young Adults
During her presentation “Adolescent and Young Adult Survivorship: What Do We Still Need to Know?” at the 2017 Cancer Survivorship Symposium: Advancing Care and Research, Emily S. Tonorezos, MD, MPH, a general internist in the Adult Long-Term Follow-Up Program at Memorial Sloan Kettering Cancer...
St. Jude Cloud, Largest Public Repository of Pediatric Cancer Genomics Data, Launched for Researchers Worldwide
On April 12, St. Jude Children’s Research Hospital launched the St. Jude Cloud, an online data-sharing and collaboration platform that provides researchers access to the world’s largest public repository of pediatric cancer genomics data. Developed as a partnership among St. Jude, DNAnexus, and...
Molecular Minimal Residual Disease Detection Shows Further Promise in Acute Myeloid Leukemia
Extended next-generation sequencing genomic profiling in acute myeloid leukemia (AML) has revealed remarkable heterogeneity and molecular complexity of the disease and provided critical insights into the genetic mechanisms underpinning of preleukemic and leukemic pathogenesis.1,2 Despite...
PARP Inhibitor Shows Promise in Patients With BRCA-Mutated Pancreatic Cancer
A targeted therapy that has been effective in fighting ovarian cancer in women, including those with BRCA1 and BRCA2 mutations, may also help patients with aggressive pancreatic cancer who harbor these mutations and have few or no other treatment options. An international team of researchers was...
Childhood Cancer STAR Act Approved by Senate and House
On May 22, the Childhood Cancer Survivorship Treatment Access and Research (STAR) Act was passed by the Senate and House and is now being sent to President Donald Trump to be signed into law. As the most comprehensive childhood cancer bill ever introduced to Congress, the Childhood Cancer STAR Act...
ASCO Through the Years: Past Presidents
Over the years many great oncology leaders have served at the helm as ASCO President. We recognize these individuals here, and extend our gratitude for their service and efforts to champion high-quality cancer care. 2018-2019: Monica M. Bertagnolli, MD 2017-2018: Bruce E. Johnson, MD 2016-2017:...
NCCN Names Wui-Jin Koh, MD, New Chief Medical Officer
The National Comprehensive Cancer Network® (NCCN®) has named Wui-Jin Koh, MD, as Senior Vice President, Chief Medical Officer, a newly created position. Dr. Koh will add additional physician representation at NCCN headquarters, which includes Chief Executive Officer Robert W. Carlson, MD. Dr. Koh...
How a Recent Study Heats up the Debate Over Intraperitoneal Chemotherapy in Newly Diagnosed Advanced Ovarian Cancer
Based on pharmacokinetic and preclinical data, there appears to be a biologic advantage to the use of intraperitoneal chemotherapy in treating some malignancies confined to the abdomen. Since most ovarian, fallopian tube, and peritoneal cancers present and recur in the peritoneal cavity, this...
The American Society of Clinical Oncology at a Glance
The American Society of Clinical Oncology (ASCO) held its first scientific Annual Meeting on April 9, 1965, in the Bellevue Stratford Hotel in Philadelphia. More than 70 members and invited guests attended the inaugural event, which featured three presentations on leukemia and multiple myeloma. The ...
2018 Fellows of the American Society of Clinical Oncology (FASCO) Recognized During Annual Meeting in Chicago
The Fellow of the American Society of Clinical Oncology (FASCO) distinction recognizes ASCO members for their extraordinary volunteer service, dedication, and commitment to ASCO. Their efforts benefit ASCO, the specialty of oncology, and, most importantly, the individuals at risk for, or with...
Update on ATLAS Trial of Axitinib for RCC Recurrence Risk
Pfizer recently announced that the independent data monitoring committee for the phase III ATLAS trial, which is evaluating axitinib (Inlyta) as adjuvant therapy for patients at high risk of recurrent renal cell carcinoma (RCC) after nephrectomy, recommended stopping the trial at a planned interim...
ASCO Honors Leaders in Cancer Care With 2018 Special Awards
ASCO AND ASCO’s Conquer Cancer Foundation recognized winners of ASCO’s 2018 Special Awards and Conquer Cancer’s Women Who Conquer Cancer Mentorship Awards during the 2018 ASCO Annual Meeting, June 1 to June 4, in Chicago. The recipients of these awards included researchers, patient advocates, and...
Fox Chase Cancer Center Announces 2018 Award Recipients for Translational Clinical Protocol Development
Fox Chase Cancer Center recently announced the awardees of the 2018 translational clinical protocol development based on basic and preclinical research results. Translational research disease groups were created with a multidisciplinary group of clinical and research-based faculty, with a focus on...
Help Your Patients Catch Up on the Latest Research From the 2018 ASCO Annual Meeting
The Cancer.Net Blog (available at Cancer.Net/Blog) features daily posts covering research highlighted at the 2018 ASCO Annual Meeting where patients and caregivers can learn what this research means for their care and treatment. The Cancer.Net Blog also offers continuing coverage from the ASCO...
Submit Your Application Today for the Alexandria Quality Training Program Session
Applications for the session of ASCO’s Quality Training Program (QTP) being held at ASCO headquarters in Alexandria, Virginia, are being accepted now. The deadline for submission is June 4, but applicants are encouraged to submit early to prepare for Session 1. Once applicants are accepted, they...
New Updates to Common Rule for Researchers
THIS PAST January, the Department of Health and Human Services (HHS), along with more than a dozen other federal agencies, finalized updates to the Common Rule, which protects human participants in biomedical research. This marked the first time that the Common Rule has been updated in nearly 3...
Enhance Your Annual Meeting Experience With Attendee Resources
More than 39,000 oncology professionals will gather in Chicago for the 2018 ASCO Annual Meeting. The theme for this year’s meeting, selected by 2017–2018 ASCO President Bruce E. Johnson, MD, FASCO, sets an exciting tone for the presentation of advances in the field of cancer care. Delivering...
What to Download and Where to Shop, Dine, and Network at #ASCO18
Network The Conquer Cancer Donor Lounge! (S401) Enjoy light refreshments, computer access, and a quiet place to network with friends and colleagues. Not a donor? Not a problem! Stop by the Donor Lounge between 8:30 AM–5:00 PM or visit CONQUER.ORG/ASCO to make your gift. Shop Pick up a copy of the...
Register Now for the ASCO Research Community Forum 2018 Annual Meeting
Register now to join research colleagues from across the United States at the ASCO Research Community Forum Annual Meeting. The meeting offers physician researchers and research staff from a variety of programs a unique platform to collaborate and develop solutions to common challenges with...
Four Reasons to Use Social Media at the ASCO Annual Meeting
Join the discussion: Use #ASCO18 on Twitter and Instagram to follow and participate in the Annual Meeting conversation in real time. During last year’s Annual Meeting, more than 17,000 health-care professionals, researchers, news outlets, patients, advocates, and other participants sent more than...
A Commitment to Innovation, Gender Equality, and Family Legacy Inspire Endowed Young Investigator Award Gifts for ASCO’s Conquer Cancer Foundation
Individuals, foundations, and corporations continue to fuel the brightest minds in cancer research through lifetime investments in the Conquer Cancer Grants & Awards program. The roster of endowed Young Investigator Awards (YIA) grew by three in 2018, with awards gifted by Thomas G. Roberts,...
Monica M. Bertagnolli, MD, FASCO, a Cattle Rancher’s Daughter, Becomes ASCO President
ASCO President-Elect Monica M. Bertagnolli, MD, FASCO, was born and reared in Wyoming, where her family ran a cattle ranch in the foothills of the snow-topped peaks of the Wind River Range (or “Winds” for short), a place of breathtakingly uncluttered vistas where the chief feature is the air...
Baylor/St. Luke’s Medical Center Establishes Annual Oncology Lecture
Baylor St. Luke’s Medical Centerhas established the Philip Salem Annual Oncology Lecture in honor of Philip A. Salem, MD, a physician, researcher, educator, and international statesman in cancer medicine; Director Emeritus of Cancer Research at Baylor/St. Luke’s Episcopal Hospital in Houston; and...
Susan G. Komen Announces New Advisors, Scholars in Breast Cancer
Susan G. Komen recently announced new advisory roles for 12 leaders in breast cancer. These women and men will join an esteemed group of breast cancer researchers, clinicians, and advocates who help guide the organization’s education and advocacy work, public health efforts, and research programs. ...
Leena Gandhi, MD, PhD, to Lead Lilly Immuno-Oncology
Eli Lilly and Company recently announced that Leena Gandhi, MD, PhD, a thoracic oncologist with a focus on immunotherapy and early drug development, will join Lilly Oncology in June 2018 to lead an immuno-oncology medical development. Dr. Gandhi is currently Director of Thoracic Medical Oncology...
New Leadership Joins Hassenfeld Children’s Hospital at NYU Langone and Perlmutter Cancer Center
Elizabeth A. Raetz, MD, Professor in the Department of Pediatrics at the University of Utah and Primary Children’s Hospital, and Theodore P. Nicolaides, MD, Assistant Professor in the Department of Pediatrics at the University of California, San Francisco, have joined Hassenfeld Children’s...
Treatment Centers Authorized to Administer CAR T-Cell Therapy
The following medical facilities are certified, as of March 2020, to administer the U. S. Food and Drug Administration-approved chimeric antigen receptor (CAR) T-cell therapy: axicabtagene ciloleucel (Yescarta or “A”) for eligible patients with non-Hodgkin lymphoma, and tisagenlecleucel (Kymriah or ...
Weighing the Cost and Value of CAR T-Cell Therapy
This past year’s approval by the U.S. Food and Drug Administration (FDA) of two chimeric antigen receptor (CAR) T-cell therapies heralded a new era in both effective cancer treatments and the most expensive cancer drugs ever. Tisagenlecleucel (Kymriah) was initially approved for the treatment of...
FDA Approves First Epoetin Alfa Biosimilar for the Treatment of Anemia
On May 15, 2018, the U.S. Food and Drug Administration (FDA) approved epoetin alfa-epbx (Retacrit) as a biosimilar to epoetin alfa (Epogen/-Procrit) for the treatment of anemia caused by chronic kidney disease, chemotherapy, or use of zidovudine in patients with HIV infection. The biosimilar is...
FDA Approves Daratumumab/VMP Combination for Newly Diagnosed Multiple Myeloma
On May 7, the U.S. Food and Drug Administration(FDA) approved daratumumab (Darzalex) in combination with bortezomib (Velcade), a proteasome inhibitor; melphalan, an alkylating agent; and prednisone—VMP—for the treatment of patients with newly diagnosed multiple myeloma who are ineligible for...
Both Patients and Clinicians Face Challenges in Recognizing and Reporting Immune-Related Adverse Events
The publication of ASCO’s toxicity management guidelines for immune checkpoint antibodies by Brahmer and colleagues,1 reviewed in this issue of The ASCO Post, has been long awaited, considering more than 15 distinct indications have been granted by the U.S. Food and Drug Administration (FDA). The ...
ASCO Clinical Practice Guideline on Managing Immune-Related Adverse Events: Next Big Step for Immune Checkpoint Inhibitors
The publication of the ASCO clinical practice guideline for the management of immune therapy–related adverse events—reviewed in this issue of The ASCO Post—represents an important next step in the incorporation of checkpoint blocking antibodies as standard cancer treatment modalities.1 The U.S....
ASCO Clinical Practice Guideline: Management of Immune-Related Adverse Events From Immune Checkpoint Inhibitor Therapy
As reported in the Journal of Clinical Oncology by Julie R. Brahmer, MD, of Johns Hopkins Kimmel Cancer Center, and colleagues, ASCO has released a clinical practice guideline on management of immune-related adverse events in patients receiving immune checkpoint inhibitor therapy.1 Immune...
Robert M. Arnold, MD, Receives 2018 Association of Specialty Professors Award
Robert M. Arnold, MD, a researcher and physician at the University of Pittsburgh Medical Center (UPMC), has been recently recognized by the Alliance for Academic Internal Medicine for his efforts to train clinicians to have difficult end-of-life conversations. Dr. Arnold accepted the 2018 Eric G....
Here’s How ASCO Is Joining With Other Organizations to Reduce Obesity and Cancer Rates
GUEST EDITOR Prevention in Oncology is guest edited by Jennifer A. Ligibel, MD, Chair of ASCO’s Energy Balance Working Group and a member of ASCO’s Cancer Survivorship and Cancer Prevention Committees. Dr. Ligibel is Director of the Leonard P. Zakim Center for Integrative Therapies at Dana-Farber...
